莫达菲尼尔与安非他-德克斯特罗安非他治疗异常性高睡眠症和麻醉症类型2:一个随机的,盲目的,非劣势试验
Lynn Marie Trotti1,2, Tyler Blake3, Romy Hoque3,4
1Department of Neurology, Emory University School of Medicine, 12 Executive Park Dr NE, Atlanta, GA, 30329, USA. Lbecke2@emory.edu.
CNS drugs
|September 21, 2024
概括
没有发现安非他胺-德克斯特罗安非他胺在2型麻醉症和异常性高睡眠症症状改善方面不低于莫达菲尼尔. 然而,它在其他症状指标上显示出非劣势,有助于治疗决策.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 麻醉症2型和异常性高睡眠症治疗需要进一步研究,特别是关于安非他命和比较有效性的研究.
- 在这些情况下,需要研究评估治疗方法,而不仅仅是睡眠.
研究的目的:
- 为了比较modafinil和安非他胺-dextroamphetamine在治疗2型麻醉症和异常性高睡眠症方面的有效性.
- 与莫达菲尼尔相比,评估安非他-德克斯特罗安非他的非劣势性.
主要方法:
- 一个为期12周的随机,双盲,非劣等性试验,涉及44名患有2型麻醉症或异常性高睡眠症的成年人.
- 参与者接受了单独定位的莫达菲尼尔或安非他-德克斯特罗安非他剂量.
- 主要结局:爱普沃思睡眠度量表的变化;次要结局:患者的总体印象,超眠症严重程度指数和睡眠惯性问卷.
主要成果:
- 对于初级结局 (爱普沃思嗜睡量表) 没有证明安非他-德克斯特罗安非他与莫达菲尼尔的非劣势.
- 氨基胺 - 德克斯特罗氨基胺对于包括疾病严重程度,嗜睡,睡眠惯性,高睡眠严重程度指数和睡眠惯性问卷在内的二次结局是非劣.
- 莫达菲尼尔 (31.8%) 的不良事件中断率高于安非他-德克斯托安非他 (9.1%). 焦虑在莫达菲尼尔治疗中更频繁,食欲抑制在安非他-德克斯特罗安非他治疗中更频繁.
结论:
- 氨基胺 - 德克斯特罗氨基胺在主要的嗜睡测量中不符合与modafinil相比的非劣质标准.
- 尽管没有达到主要终点,但安非他-德克斯特罗安非他在其他几个关键症状指标上表现出非劣势.
- 研究结果支持在2型麻醉症和异常性高睡眠症的治疗选择中共享决策.
相关概念视频
01:07Narcolepsy
94
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
94
01:19Management of Insomnia
235
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
235
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
157
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
157
01:25Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
01:28Adrenergic Agonists: Mixed-Action Agents
689
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
689
02:07Blind Procedures
10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K